4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Stress Echo for Ischemic Mitral Valve Surgery (SURVIVE)

Stress Echo for Ischemic Mitral Valve Surgery (SURVIVE)

Study Description
Brief Summary:
Comparison patients with CABG alone vs. CABG+mitral surgery with non-massive ischaemic mitral regurgitation (IMR) depending on stress echo data.

Condition or disease Intervention/treatment Phase
Ischemic Mitral Regurgitation Procedure: Mitral surgery Not Applicable

Show Show detailed description
Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Stress Echo for Ischemic Mitral Valve Surgery
Actual Study Start Date : January 1, 2020
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2027
Arms and Interventions
Arm Intervention/treatment
No Intervention: CABG/increasing MR
non-massive IMR with increasing IMR during exercise - CABG only
Experimental: CABG+mitral surgery (MS)/increasing MR
non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
Procedure: Mitral surgery
Guidelines approved mitral surgery

No Intervention: CABG/non-increasing MR
non-massive IMR non-increasing IMR during exercise - CABG only
Experimental: CABG+MS/non-increasing MR
non-massive IMR non-increasing IMR - CABG+ mitral surgery
Procedure: Mitral surgery
Guidelines approved mitral surgery

Control 1
massive IMR at rest without increasing during exercise - CABG+ mitral surgery
Procedure: Mitral surgery
Guidelines approved mitral surgery

Control 2
massive IMR at rest with increasing during exercise - CABG+ mitral surgery
Procedure: Mitral surgery
Guidelines approved mitral surgery

Outcome Measures
Primary Outcome Measures :
  1. myocardial infarction [ Time Frame: during 3 year ]
    myocardial infarction

  2. all-cause death [ Time Frame: during 3 year ]
    all-cause death

  3. new hospital readmission [ Time Frame: during 3 year from including ]
    new hospitalization

  4. re-operation [ Time Frame: during 3 year ]
    percutaneous coronary intervention, coronary bypass surgery, heart transplant

  5. cardiac death [ Time Frame: during 3 year ]
    cardiac death


Secondary Outcome Measures :
  1. physical capacity [ Time Frame: Change from Baseline of physical capacity in Watts at 12 months, at 3 years ]
    Change in Watts during stress test

  2. end diastolic volume of left ventricle [ Time Frame: Change from Baseline of end diastolic volume of left ventricle at 12 months, at 3 years ]
    Change in milliliters by echocardiography

  3. left atrium volume [ Time Frame: Change from Baseline of left atrium volume at 12 months, at 3 years ]
    Change in milliliters by echocardiography

  4. ejection fraction at rest and during stress echo [ Time Frame: Change from Baseline of ejection fraction at 12 months, at 3 years ]
    Change in percent by echocardiography at rest and at the peak of exercise during stress test

  5. effective regurgitant orifice [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    Change in centimeter square of mitral effective regurgitant orifice by echocardiography

  6. right ventricle size [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    Change in centimeter of right ventricle by echocardiography

  7. pulmonary artery pressure pressure [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    Change in mm Hg of pulmonary pressure by echocardiography

  8. B-lines [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    counts of B-lines during by stress echocardiography

  9. Contractile reserve [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    Change in contractile reserve by stress echocardiography


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ischemic MR, ERO≥0.2 cm2 and RV≥30 ml.
  • Indication for CABG

Exclusion Criteria:

  • Unwillingness to give informed consent and to enter a regular follow-up program.
  • Contraindications for SE.
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Angela Zagatina, MD, PhD +79213297087 zag_angel@yahoo.com

Locations
Layout table for location information
Russian Federation
St. Petersburg State University Recruiting
Saint Petersburg, Russian Federation
Contact: Angela Zagatina, MD, PhD         
Sponsors and Collaborators
Saint Petersburg State University, Russia
Investigators
Layout table for investigator information
Principal Investigator: Dmitry Shmatov, MD, PhD Saint Petersburg State University, Russia
Tracking Information
First Submitted Date  ICMJE June 30, 2019
First Posted Date  ICMJE July 17, 2019
Last Update Posted Date September 25, 2020
Actual Study Start Date  ICMJE January 1, 2020
Estimated Primary Completion Date December 31, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 16, 2019)
  • myocardial infarction [ Time Frame: during 3 year ]
    myocardial infarction
  • all-cause death [ Time Frame: during 3 year ]
    all-cause death
  • new hospital readmission [ Time Frame: during 3 year from including ]
    new hospitalization
  • re-operation [ Time Frame: during 3 year ]
    percutaneous coronary intervention, coronary bypass surgery, heart transplant
  • cardiac death [ Time Frame: during 3 year ]
    cardiac death
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 16, 2019)
  • physical capacity [ Time Frame: Change from Baseline of physical capacity in Watts at 12 months, at 3 years ]
    Change in Watts during stress test
  • end diastolic volume of left ventricle [ Time Frame: Change from Baseline of end diastolic volume of left ventricle at 12 months, at 3 years ]
    Change in milliliters by echocardiography
  • left atrium volume [ Time Frame: Change from Baseline of left atrium volume at 12 months, at 3 years ]
    Change in milliliters by echocardiography
  • ejection fraction at rest and during stress echo [ Time Frame: Change from Baseline of ejection fraction at 12 months, at 3 years ]
    Change in percent by echocardiography at rest and at the peak of exercise during stress test
  • effective regurgitant orifice [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    Change in centimeter square of mitral effective regurgitant orifice by echocardiography
  • right ventricle size [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    Change in centimeter of right ventricle by echocardiography
  • pulmonary artery pressure pressure [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    Change in mm Hg of pulmonary pressure by echocardiography
  • B-lines [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    counts of B-lines during by stress echocardiography
  • Contractile reserve [ Time Frame: Change from Baseline at 12 months, at 3 years ]
    Change in contractile reserve by stress echocardiography
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Stress Echo for Ischemic Mitral Valve Surgery
Official Title  ICMJE Stress Echo for Ischemic Mitral Valve Surgery
Brief Summary Comparison patients with CABG alone vs. CABG+mitral surgery with non-massive ischaemic mitral regurgitation (IMR) depending on stress echo data.
Detailed Description

Chronic ischaemic mitral regurgitation (IMR) is a frequent complication of coronary artery disease (CAD), and is associated with a poor prognosis and outcome. The role of concomitant mitral valve surgery for IMR in patients undergoing coronary artery bypass grafting (CABG) remains controversial. After myocardial infarction IMR is associated with poor outcome and prognosis with double mortality rates, it reduces survival following surgical or percutaneous revascularization. However, there is no consensus on the cut-off value of IMR. The thresholds to define severe secondary mitral regurgitation are need to be evaluated with regards to their impact on prognosis after mitral valve intervention. The European guidelines is defined effective regurgitant orifice (ERO)-0.2 cm2 and regurgitant volume (RV)-30ml, as the threshold for severe IMR, because of severe prognosis of this group. Whereas American guidelines are defined it as ERO-0.4 cm2 and RV-60ml, as it was no evidence to impact intervention on the IMR with ERO-0.2 cm2 and RV-30ml. Partly it's explained by the dynamic nature of the secondary MR. About 30% of patients from the group with non-massive regurgitation at rest, have dramatically increasing it during exercise. However, some patient have not changes or decreasing IMR during exercise and, probably, they have not such a negative impact on the hemodynamic by IMR. The pervious comparative studies, that were the base for recommendations did not differ the patients with and without changes IMR during exercise. The current guidelines doesn't support the stress echo (SE) exams before operation for assessing necessity in mitral valve operation. It's due to lack of information that prove of influence for survival after surgery depending on IMR dynamic parameters.

IMR study hypothesis: Stress echocardiography data, including ERO, RV, pulmonary pressure (PA) pressure, beta-lines - B-lines, contractile reserve, could be indications for mitral valve intervention in patient with CAD and chronic secondary mitral regurgitation, undergoing CABG. The patients of the group with non-massive (ERO-0.2 cm2 and RV-30ml) IMR have positive effect by mitral surgery if they have increasing IMR during exercise test. The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with non-massive non-operated subgroup.

Aim: To assess the value of stress echo testing for ischemic mitral surgery indication in patients undergoing CABG.

Inclusion criteria for all projects are:

  1. Age > 18 years
  2. IMR, ERO≥0.2 cm2 and RV≥30 ml.
  3. Indication for CABG

Exclusion criteria for all projects are:

  1. Unwillingness to give informed consent and to enter a regular follow-up program.
  2. Contraindications for stress echo.

Methods and design:

  1. In a prospective multicenter international randomized study, we will recruit patients whom CABG is planned.
  2. Conventional transthoracic echo. Patients will include into two groups:

    Group 1 - "Non-massive IMR" - ERO-0.2-0.39 cm2, and RV-30-59ml. Group 2 - "Massive IMR" - ERO≥0.4 cm2 and RV≥60 ml.

  3. Randomization of Group 1 (surgery/non-surgery).
  4. Exercise stress echocardiography of all the patients (Group 1 and Group 2). regional wall motion abnormality (RWMA), ejection fraction (EF), end diastolic volume (EDV), end systolic volume (ESV), contractile reserve, B-lines, ERO, RV, PA pressure at rest and during stress.
  5. 1-year clinical outcomes
  6. 1-year transthoracic echo data.
  7. 1-year stress echocardiography data.
  8. 3-year clinical outcomes
  9. 3-year transthoracic echo data.
  10. 3-year stress echocardiography data. Primary end-points: death, myocardial infarction, new hospital readmission, heart transplant, ventricular assist device implantation, aborted sudden death, pulmonary oedema (MACE).

Secondary end-points: physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data.

Expected results. Group 1, CABG - subgroup, CABG+mitral surgery subgroup. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data in CABG+mitral surgery subgroup already in 1-year follow-up. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echo), EDV, left atrium volume, EF at rest and during stress echo, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with CABG-subgroup already in 1-year follow-up. It's expected that more pronounce changes will be in CABG+mitral surgery subgroup with previously increasing IMR. The worst results are expected in CABG-subgroup with previously increasing IMR during exercise. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc). We expected reduced MACE till 3 year in CABG+mitral surgery subgroup with increasing IMR in comparison with CABG-subgroup with increasing IMR.

Group 2, The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with CABG-subgroup with increasing IMR from group 1. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc).

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Ischemic Mitral Regurgitation
Intervention  ICMJE Procedure: Mitral surgery
Guidelines approved mitral surgery
Study Arms  ICMJE
  • No Intervention: CABG/increasing MR
    non-massive IMR with increasing IMR during exercise - CABG only
  • Experimental: CABG+mitral surgery (MS)/increasing MR
    non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
    Intervention: Procedure: Mitral surgery
  • No Intervention: CABG/non-increasing MR
    non-massive IMR non-increasing IMR during exercise - CABG only
  • Experimental: CABG+MS/non-increasing MR
    non-massive IMR non-increasing IMR - CABG+ mitral surgery
    Intervention: Procedure: Mitral surgery
  • Control 1
    massive IMR at rest without increasing during exercise - CABG+ mitral surgery
    Intervention: Procedure: Mitral surgery
  • Control 2
    massive IMR at rest with increasing during exercise - CABG+ mitral surgery
    Intervention: Procedure: Mitral surgery
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 24, 2020)
400
Original Estimated Enrollment  ICMJE
 (submitted: July 16, 2019)
240
Estimated Study Completion Date  ICMJE December 31, 2027
Estimated Primary Completion Date December 31, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Ischemic MR, ERO≥0.2 cm2 and RV≥30 ml.
  • Indication for CABG

Exclusion Criteria:

  • Unwillingness to give informed consent and to enter a regular follow-up program.
  • Contraindications for SE.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Angela Zagatina, MD, PhD +79213297087 zag_angel@yahoo.com
Listed Location Countries  ICMJE Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04023058
Other Study ID Numbers  ICMJE 2/2019
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Study Protocol, Clinical study report
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Informed Consent Form (ICF)
Supporting Materials: Clinical Study Report (CSR)
Time Frame: 3 year
Responsible Party Zagatina Angela, Saint Petersburg State University, Russia
Study Sponsor  ICMJE Saint Petersburg State University, Russia
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Dmitry Shmatov, MD, PhD Saint Petersburg State University, Russia
PRS Account Saint Petersburg State University, Russia
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP